Leticia Barba

1.2k total citations · 1 hit paper
6 papers, 890 citations indexed

About

Leticia Barba is a scholar working on Immunology, Oncology and Infectious Diseases. According to data from OpenAlex, Leticia Barba has authored 6 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Oncology and 1 paper in Infectious Diseases. Recurrent topics in Leticia Barba's work include CAR-T cell therapy research (3 papers), Immune Cell Function and Interaction (3 papers) and Phagocytosis and Immune Regulation (2 papers). Leticia Barba is often cited by papers focused on CAR-T cell therapy research (3 papers), Immune Cell Function and Interaction (3 papers) and Phagocytosis and Immune Regulation (2 papers). Leticia Barba collaborates with scholars based in Switzerland, Italy and Germany. Leticia Barba's co-authors include Nathalie Rufer, Lukas Baitsch, Amandine Legat, Daniel E. Speiser, Petra Baumgaertner, Hanifa Bouzourène, Sunil K. Raghav, Sébastien Wieckowski, Bart Deplancke and Estelle Devêvre and has published in prestigious journals such as Journal of Clinical Investigation, PLoS ONE and Journal of Virology.

In The Last Decade

Leticia Barba

6 papers receiving 876 citations

Hit Papers

Exhaustion of tumor-specific CD8+ T cells in metastases f... 2011 2026 2016 2021 2011 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leticia Barba Switzerland 6 676 643 150 45 42 6 890
Elien M. Doorduijn Netherlands 10 663 1.0× 496 0.8× 222 1.5× 41 0.9× 51 1.2× 12 867
Weiqing Jing United States 15 479 0.7× 452 0.7× 225 1.5× 35 0.8× 63 1.5× 29 825
Jean‐Christophe Beltra United States 8 737 1.1× 595 0.9× 195 1.3× 34 0.8× 47 1.1× 9 962
Myriam Lawand France 10 509 0.8× 372 0.6× 122 0.8× 72 1.6× 40 1.0× 14 727
Sarah J. Flies United States 7 864 1.3× 773 1.2× 150 1.0× 93 2.1× 30 0.7× 7 1.2k
Anthony Miliotto United States 13 570 0.8× 559 0.9× 255 1.7× 63 1.4× 81 1.9× 23 866
Jens Pahl Germany 12 565 0.8× 418 0.7× 187 1.2× 71 1.6× 37 0.9× 20 794
Marten Visser Netherlands 10 867 1.3× 869 1.4× 303 2.0× 53 1.2× 60 1.4× 15 1.1k
Henning Zelba Germany 14 650 1.0× 594 0.9× 180 1.2× 53 1.2× 38 0.9× 23 883
Aurélie Durgeau France 7 776 1.1× 661 1.0× 181 1.2× 89 2.0× 33 0.8× 7 1.0k

Countries citing papers authored by Leticia Barba

Since Specialization
Citations

This map shows the geographic impact of Leticia Barba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leticia Barba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leticia Barba more than expected).

Fields of papers citing papers by Leticia Barba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leticia Barba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leticia Barba. The network helps show where Leticia Barba may publish in the future.

Co-authorship network of co-authors of Leticia Barba

This figure shows the co-authorship network connecting the top 25 collaborators of Leticia Barba. A scholar is included among the top collaborators of Leticia Barba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leticia Barba. Leticia Barba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Hatterer, Eric, Xavier Chauchet, Françoise Richard, et al.. (2020). Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. mAbs. 12(1). 1739408–1739408. 33 indexed citations
2.
Hatterer, Eric, Leticia Barba, Nelly Noraz, et al.. (2018). Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. mAbs. 11(2). 322–334. 31 indexed citations
3.
Maroun, Céline Yacoub, Romain Vuillefroy de Silly, Simone Jueliger, et al.. (2016). Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. PLoS ONE. 11(8). e0162105–e0162105. 20 indexed citations
4.
Sommerstein, Rami, Stephan Ölschläger, Andreas Bergthaler, et al.. (2014). Evolution of Recombinant Lymphocytic Choriomeningitis Virus/Lassa Virus In Vivo Highlights the Importance of the GPC Cytosolic Tail in Viral Fitness. Journal of Virology. 88(15). 8340–8348. 15 indexed citations
5.
Baitsch, Lukas, Amandine Legat, Leticia Barba, et al.. (2012). Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization. PLoS ONE. 7(2). e30852–e30852. 141 indexed citations
6.
Baitsch, Lukas, Petra Baumgaertner, Estelle Devêvre, et al.. (2011). Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. Journal of Clinical Investigation. 121(6). 2350–2360. 650 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026